Evidence map›Paper›PMID 28196842›Full record

ArticleJournal of the American Society of Nephrology : JASN2017

Identifying the Intracellular Function of APOL1.

Leslie A Bruggeman, John F O'Toole, John R Sedor

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Leslie A BruggemanDepartment of Medicine, MetroHealth Medical Center and leslie.bruggeman@case.edu.
John F O'TooleDepartment of Medicine, MetroHealth Medical Center and.
John R SedorDepartment of Medicine, MetroHealth Medical Center and.

Funding

Mechanisms of APOL1-mediated kidney diseaseR01DK108329 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BRUGGEMAN, LESLIE A, O'TOOLE, JOHN F. · 2015 to 2019
$2.0M
Kidney disease mechanisms associated with human genetic variationR01DK097836 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BRUGGEMAN, LESLIE A, O'TOOLE, JOHN F. · 2014 to 2017
$2.0M
Kidney disease mechanisms associated with human genetic variationR56DK097836 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI BRUGGEMAN, LESLIE A, O'TOOLE, JOHN F. · 2012 to 2012
$198k
NIDDK NIH HHS R01 DK097836NIDDK NIH HHS R01 DK108329NIDDK NIH HHS R56 DK097836
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Apolipoprotein L1ApolipoproteinsCell DeathGenetic Predisposition to DiseaseHumansHypertrophyLipoproteins, HDLAPOL1 protein, humanApolipoprotein L1ApolipoproteinsLipoproteins, HDLcell deathchronic kidney diseasehuman genetics

Identifiers

PMID28196842
PMCPMC5373468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.